Market News / Story
David (Zhongwei) Zhang appointed to Aard board as Class II director
·
Aard appointed David (Zhongwei) Zhang as a Class II director, effective October 7, 2026. IndividualDavid (Zhongwei) Zhang, Ph.D., MBARoleClass II directorType of ChangeAppointedEffective DateOctober 7, 2026ReasonNot disclosedReplacement InfoNot disclosedBackground DetailsOver 25 years in clinical program design and biometrics; CSO at Abivax since Jul 2024; prior senior biometrics roles at Alumis, MyoKardia, Roche, Eli Lilly, Abbott; Ph.D. in biostatistics;…